These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 15747097)

  • 41. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.
    Rao Q; Liu B; Cheng L; Zhu Y; Shi QL; Wu B; Jiang SJ; Wang Y; Wang X; Yu B; Zhang RS; Ma HH; Lu ZF; Tu P; Wang JD; Zhou XJ
    Am J Surg Pathol; 2012 Sep; 36(9):1327-38. PubMed ID: 22895266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
    Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
    Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biological characteristics of pediatric renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.
    Song HC; Sun N; Zhang WP; He L; Fu L; Huang C
    J Pediatr Surg; 2014 Apr; 49(4):539-42. PubMed ID: 24726108
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas.
    Medendorp K; van Groningen JJ; Schepens M; Vreede L; Thijssen J; Schoenmakers EF; van den Hurk WH; Geurts van Kessel A; Kuiper RP
    Cytogenet Genome Res; 2007; 118(2-4):157-65. PubMed ID: 18000366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation.
    Inamura K; Fujiwara M; Togashi Y; Nomura K; Mukai H; Fujii Y; Yamamoto S; Yonese J; Fukui I; Ishikawa Y
    Am J Surg Pathol; 2012 Jan; 36(1):35-42. PubMed ID: 22173116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
    Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of t(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient.
    Pecciarini L; Cangi MG; Lo Cunsolo C; Macri' E; Dal Cin E; Martignoni G; Doglioni C
    Genes Chromosomes Cancer; 2007 May; 46(5):419-26. PubMed ID: 17285572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
    Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
    [No Abstract]   [Full Text] [Related]  

  • 50. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
    Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
    Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: a study of 11 cases and review of literature].
    Rao Q; Zhou XJ; Wu B; Ma HH; Zhou HB; Liu XH; Chen JY
    Zhonghua Bing Li Xue Za Zhi; 2007 Apr; 36(4):244-6. PubMed ID: 17706115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: radiological findings mimicking papillary subtype.
    Kato H; Kanematsu M; Yokoi S; Miwa K; Horie K; Deguchi T; Hirose Y
    J Magn Reson Imaging; 2011 Jan; 33(1):217-20. PubMed ID: 21182142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy.
    Rais-Bahrami S; Drabick JJ; De Marzo AM; Hicks J; Ho C; Caroe AE; Argani P
    Urology; 2007 Jul; 70(1):178.e3-6. PubMed ID: 17656236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pseudocapsule of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: a clue for tumor enucleation?
    Cheng X; He J; Gan W; Fan X; Yang J; Zhu B; Guo H
    Int J Clin Exp Pathol; 2015; 8(5):5403-10. PubMed ID: 26191243
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.
    Al-Maghrabi J; Mufti S; Gomaa W
    Pol J Pathol; 2018; 69(4):376-383. PubMed ID: 30786687
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Translocation carcinomas of the kidney after chemotherapy in childhood.
    Argani P; Laé M; Ballard ET; Amin M; Manivel C; Hutchinson B; Reuter VE; Ladanyi M
    J Clin Oncol; 2006 Apr; 24(10):1529-34. PubMed ID: 16575003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
    Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
    Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. XP11.2 translocation renal cell carcinoma: clinical experience of Taipei Veterans General Hospital.
    Hung CC; Pan CC; Lin CC; Lin AT; Chen KK; Chang YH
    J Chin Med Assoc; 2011 Nov; 74(11):500-4. PubMed ID: 22100019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic pitfall on the histological spectrum of adult-onset renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.
    Kuroda N; Katto K; Tanaka Y; Yamaguchi T; Inoue K; Ohara M; Mizuno K; Hes O; Michal M; Lee GH
    Med Mol Morphol; 2010 Jun; 43(2):86-90. PubMed ID: 20683695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MicroRNA expression profiling of Xp11 renal cell carcinoma.
    Marchionni L; Hayashi M; Guida E; Ooki A; Munari E; Jabboure FJ; Dinalankara W; Raza A; Netto GJ; Hoque MO; Argani P
    Hum Pathol; 2017 Sep; 67():18-29. PubMed ID: 28411178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.